ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhen Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9946-1362; OpenAlex author ID A5002718933. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2025: 1 paper

Papers 1

Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.phymed.2025.157048 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yuan Zhang · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗
Waimei Si · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗
He Ba · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗
Xin Li · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗
Peiwen Yang · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗
Linjie Ruan · 1 shared paper, 2025 · strength 0.28
- Paper Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcin… DOI 10.1016/j.phymed.2025.157048 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.